个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Retinoblastoma in Asia: Clinical Presentation and Treatment Outcomes in 2112 Patients from 33 Countries

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Kaliki Swathi[1,*1] * ; Vempuluru Vijitha S[1] ; Mohamed Ashik[1] ; Al-Jadiry Mazin Faisal[2] ; Bowman Richard[3,4] ; Chawla Bhavna[5] ; Hamid Syed Ahmer[6] ; Ji Xunda[7] ; Kapelushnik Noa[8] ; Kebudi Rejin[9] ; Sthapit Purnima Rajkarnikar[10] ; Rojanaporn Duangnate[11] ; Sitorus Rita S[12] ; Yousef Yacoub Abdallah[13] ; Fabian Ido Didi[3,8] ; for the Global Retinoblastoma Study Group[1] ;
机构： [1]The Operation Eyesight Universal Institute for Eye Cancer, L.V.PrasadEye Institute, Hyderabad, India [2]Pediatric Oncology Unit, Children Welfare Teaching Hospital, MedicalCity, College of Medicine, University of Baghdad, Bagdad, Iraq [3]International Centre for Eye Health, London School of Hygiene &Tropical Medicine, London, United Kingdom [4]Department of Ophthalmology, Great Ormond Street Children’s Hospital,London, United Kingdom [5]Ocular Oncology Service, Dr.Rajendra Prasad Centre for OphthalmicSciences, All India Institute of Medical Sciences, New Delhi, India [6]Department of Ophthalmology, The Indus Hospital, Karachi, Pakistan [7]Department of Ophthalmology, Xinhua Hospital, Shanghai Jiao TongUniversity School of Medicine, Shanghai, China [8]Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, TelAviv University, Tel-Aviv, Israel [9]Department of Pediatric Hematology-Oncology, Oncology Institute,Istanbul University, Istanbul, Turkey [10]Department of Ophthalmology, Tilganga Institute of Ophthalmology,Kathmandu, Nepal [11]Department of Ophthalmology, Faculty of Medicine, RamathibodiHospital, Mahidol University, Bangkok, Thailand [12]Department of Ophthalmology, Faculty of Medicine UniversitasIndonesia, Dr.Cipto Mangunkusumo National General Hospital, Jakarta,Indonesia [13]Department of Ophthalmology, King Hussein Cancer Center, Amman,Jordan
出处：
DOI： 10.1016/j.ophtha.2023.10.015
ISSN：

摘要：
To describe the clinical presentation and treatment outcomes of children who received a diagnosis of retinoblastoma in 2017 throughout Asia.Multinational, prospective study including treatment-naïve patients in Asia who received a diagnosis of retinoblastoma in 2017 and were followed up thereafter.A total of 2112 patients (2797 eyes) from 96 retinoblastoma treatment centers in 33 Asian countries.Chemotherapy, radiotherapy, enucleation, and orbital exenteration.Enucleation and death.Within the cohort, 1021 patients (48%) were from South Asia (SA), 503 patients (24%) were from East Asia (EA), 310 patients (15%) were from Southeast Asia (SEA), 218 patients (10%) were from West Asia (WA), and 60 patients (3%) were from Central Asia (CA). Mean age at presentation was 27 months (median, 23 months; range, < 1-261 months). The cohort included 1195 male patients (57%) and 917 female patients (43%). The most common presenting symptoms were leukocoria (72%) and strabismus (13%). Using the American Joint Committee on Cancer Staging Manual, Eighth Edition, classification, tumors were staged as cT1 (n = 441 [16%]), cT2 (n = 951 [34%]), cT3 (n = 1136 [41%]), cT4 (n = 267 [10%]), N1 (n = 48 [2%]), and M1 (n = 129 [6%]) at presentation. Retinoblastoma was treated with intravenous chemotherapy in 1450 eyes (52%) and 857 eyes (31%) underwent primary enucleation. Three-year Kaplan-Meier estimates for enucleation and death were 33% and 13% for CA, 18% and 4% for EA, 27% and 15% for SA, 32% and 22% for SEA, and 20% and 11% for WA (P < 0.0001 and P < 0.0001), respectively.At the conclusion of this study, significant heterogeneity was found in treatment outcomes of retinoblastoma among the regions of Asia. East Asia displayed better outcomes with higher rates of globe and life salvage, whereas Southeast Asia showed poorer outcomes compared with the rest of Asia.The author(s) have no proprietary or commercial interest in any materials discussed in this article.Copyright © 2023 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 1 区 眼科学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 眼科学
第一作者：
第一作者机构： [1]The Operation Eyesight Universal Institute for Eye Cancer, L.V.PrasadEye Institute, Hyderabad, India [*1]The Operation Eyesight Universal Institute for Eye Cancer, L.V. Prasad Eye Institute, Hyderabad, Telangana 500034, India.
通讯作者：
通讯机构： [1]The Operation Eyesight Universal Institute for Eye Cancer, L.V.PrasadEye Institute, Hyderabad, India [*1]The Operation Eyesight Universal Institute for Eye Cancer, L.V. Prasad Eye Institute, Hyderabad, Telangana 500034, India.
推荐引用方式(GB/T 7714)：
Kaliki Swathi,Vempuluru Vijitha S,Mohamed Ashik,et al.Retinoblastoma in Asia: Clinical Presentation and Treatment Outcomes in 2112 Patients from 33 Countries[J].Ophthalmology.2023,doi:10.1016/j.ophtha.2023.10.015.
APA：
Kaliki Swathi,Vempuluru Vijitha S,Mohamed Ashik,Al-Jadiry Mazin Faisal,Bowman Richard...&for the Global Retinoblastoma Study Group.(2023).Retinoblastoma in Asia: Clinical Presentation and Treatment Outcomes in 2112 Patients from 33 Countries.Ophthalmology,,
MLA：
Kaliki Swathi,et al."Retinoblastoma in Asia: Clinical Presentation and Treatment Outcomes in 2112 Patients from 33 Countries".Ophthalmology .(2023)

资源点击量：23624 今日访问量：3 总访问量：1285 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持：重庆聚合科技有限公司 地址：北京市东城区东交民巷1号(100730)